Review

Get Permission
Rev Diabet Stud, 2010, 7(2):132-143 DOI 10.1900/RDS.2010.7.132

Mesenchymal Stem Cells as Feeder Cells for Pancreatic Islet Transplants

Valeria Sordi, Lorenzo Piemonti

San Raffaele Diabetes Research Institute (HSR-DRI), Division of Immunology, Transplantation and Infectious Disease, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
Address correspondence to: Valeria Sordi, e-mail: sordi.valeria@hsr.it

Manuscript submitted July 20, 2010; resubmitted August 7, 2010; accepted August 9, 2010.

Keywords: stem cell, feeder, islet, co-transplantation, revascularization, bone marrow, immunomodulation

Abstract

Allogeneic islet transplantation serves as a source of insulin-secreting beta-cells for the maintenance of normal glucose levels and treatment of diabetes. However, limited availability of islets, high rates of islet graft failure, and the need for life-long non-specific immunosuppressive therapy are major obstacles to the widespread application of this therapeutic approach. To overcome these problems, pancreatic islet transplantation was recently suggested as a potential target of the "therapeutic plasticity" of adult stem cells. In fact, new results suggest that stem/precursor cells, and mesenchymal stem cells in particular, co-transplanted with islets can promote tissue engraftment and beta-cell survival via bystander mechanisms, mainly exerted by creating a milieu of cytoprotective and immunomodulatory molecules. This evidence consistently challenges the limited view that stem/precursor cells work exclusively through beta-cell replacement in diabetes therapy. It proposes that stem cells also act as "feeder" cells for islets, and supporter of graft protection, tissue revascularization, and immune acceptance. This article reviews the experience of using stem cell co-transplantation as strategy to improve islet transplantation. It highlights that comprehension of the mechanisms involved will help to identify new molecular targets and promote development of new pharmacological strategies to treat type 1 and type 2 diabetes patients.

Fulltext: HTML , PDF (937KB)


This article has been cited by other articles:

IL-12 involvement in myogenic differentiation of C2C12 in vitro

Romanazzo S, Forte G, Morishimace K, Taniguchi A

Biomaterial Sci 2015. 2015(3):469-479

Bone marrow- and cord blood-derived stem cell transplantation for diabetes therapy

Cantarelli E, Pellegrini S, Citro A, Sordi V, Piemonti L

CellR4 2015. 3(1):e1408

Manipulation of cell sorting within mesenchymal stromal cell-islet cell multicellular spheroids

Hoffecker IT, Iwata H

Tissue Eng Part A 2014. 20(11-12):1643-1653

Design of bioartificial pancreas with functional micro/nano-based encapsulation of islets

Kepsutlu B, Nazli C, Bal T, Kizilel S

Curr Pharm Biotechnol 2014. 15(7):590-608

Selected cytokines in patients with pancreatic cancer: a preliminary report

Błogowski W, Deskur A, Budkowska M, Sałata D, Madej-Michniewicz A, Dabkowski K, Dolegowska B, Starzynska T

Plos One 2014. 9(5):e97613

In vivo bioluminescence imaging of transplanted mesenchymal stem cells as a potential source for pancreatic regeneration

Lee S, Youn H, Chung T, Hwang do W, Oh SW, Kang KW, Chung JK, Lee DS

Mol Imaging 2014. 2014:13

The impact of oxidative stress on islet transplantation and monitoring the graft survival by non-invasive imaging

Ramkumar KM, Sekar TV, Bhakkiyalakshmi E, Foygel K, Rajaguru P, Berger F, Paulmurugan R

Curr Med Chem 2013. 20(9):1127-1146

Contribution of murine bone marrow mesenchymal stem cells to pancreas regeneration after partial pancreatectomy in mice

Han F, Wang CY, Yang L, Zhan SD, Zhang M, Tian K

Cell Biol Int 2012. 36(9):823-831

A Step-up Approach for Cell Therapy in Stroke: Translational Hurdles of Bone Marrow-Derived Stem Cells

Glover LE, Tajiri N, Weinbren NL, Ishikawa H, Shinozuka K, Kaneko Y, Watterson DM, Borlongan CV

Transl Stroke Res 2012. 3(1):90-98

Genetically engineered islets and alternative sources of insulin-producing cells for treating autoimmune diabetes: quo vadis?

Chou FC, Huang SH, Sytwu HK

Int J Endocrinol 2012. 2012:296485

The great migration of bone marrow-derived stem cells toward the ischemic brain: therapeutic implications for stroke and other neurological disorders

Borlongan CV, Glover LE, Tajiri N, Kaneko Y, Freeman TB

Prog Neurobiol 2011. 95(2):213-228

New hope for type 2 diabetics: targeting insulin resistance through the immune modulation of stem cells

Zhao Y, Jiang Z, Guo C

Autoimmun Rev 2011. 11(2):137-142

A step-up approach for cell therapy in stroke: translational hurdles of bone marrow-derived stem cells

Glover LE, Tajiri N, Weinbren NL, Ishikawa H, Shinozuka K, Kaneko Y, Watterson DM, Borlongan CV

Transl Stroke Res 2011. In press

Current status of immunomodulatory and cellular therapies in preclinical and clinical islet transplantation

Chhabra P, Brayman KL

J Transplant 2011. 2011:637692

Beta-cell generation: can rodent studies be translated to humans?

Carlotti F, Zaldumbide A, Ellenbroek JH, Spijker HS, Hoeben RC, de Koning EJ

J Transplant 2011. 2011:892453

Human placenta-derived mesenchymal stem cells and islet-like cell clusters generated from these cells as a novel source for stem cell therapy in diabetes

Kadam S, Muthyala S, Nair P, Bhonde R

Rev Diabet Stud 2010. 7(2):168-182